Johnson & Johnson
NYSE: JNJ
$152.49
-$2.28 (-1.5%)
Real Time Data Delayed 15 Min.
JNJ Articles
James Tobin, the CEO of Boston Scientific (NYSE:BSX) is likely to find himself in front of the shareholder firing squad in 2008. In early 2004 this stock was above $40 and had enjoyed an incredible...
Published:
Last Updated:
According to Reuters, OPEC will probably keep oil output at current levels. Reuters writes that a goverment plan to help sub-prime borrowers will probably freeze their rates for five years. Reuters...
Published:
Abbott Labs (ABT) which just launched a new stent product, Xience V, has laid off 1,200 people because of slowness in the stent market. Stranger than fiction. According to MarketWatch, Abbott says it...
Published:
Abbot Labs (ABT) is trying to get into the stent business. The market has been dominated by Boston Scientific (BSX) and Johnson & Johnson (JNJ). Stents are small mess implants which are designed...
Published:
Several studies which showed that stents could cause blood clotting in the heart have done significant damage to the revenue for those products at Boston Scientific (BSX) and Johnson & Johnson...
Published:
According to Reuters, BHP Billiton (BHP) will not sell its petroleum division, as had been rumored, to finance a bid for Rio Tinto (RTP). Reuters writes that most of the Hershey (HSY) was pushed out...
Published:
The markets haven’t fallen apart after yesterday’s 360 point dive on the DJIA, but we are still trading a tad lower today. Now that Cisco Systems is showing you can’t just automatically hide...
Published:
Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson. It now has long-term debt of almost $8.3 billion. Troubles in its...
Published:
With the markets down so much today on the financial stock fallout after the Citi downgrade/concern and with oil stocks listing lower after the Exxon miss, we wanted to show a brief comparison of...
Published:
Last Updated:
"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up in South Florida. Still, restoring luster to the...
Published:
Shares of Amgen Inc. (NASDAQ:AMGN) are under bit of pressure this morning, although not from any direct news from the company itself. Luckily for Amgen, much of the bad news may already be baked...
Published:
Last Updated:
Johnson & Johnson (JNJ) announced third-quarter sales of $15.0 billion, an increase of 12.7% as compared to the third quarter of 2006.Net earnings and diluted earnings per share for the third...
Published:
Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns about whether the product has long-term risks or whether it is more effective...
Published:
Medtronic (MDT) has decided to get into the stent business, making the little mesh tubes that keep arteries open. It is a perverse selection because Boston Scientific (BSX) and Johnson & Johnson...
Published:
Stent sales for Boston Scientific (BSX) and Johnson & Johnson (JNJ) have taken a big drop since research began to emerge that the products could cause heart problems. There have been several...
Published: